No headlines found.
PRNewswire (Thu, 14-Sep 5:03 PM ET)
PRNewswire (Thu, 7-Sep 8:40 AM ET)
PRNewswire (Tue, 5-Sep 7:00 AM ET)
PRNewswire (Fri, 11-Aug 7:00 AM ET)
PRNewswire (Thu, 27-Jul 7:00 AM ET)
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. The company competes in the segments of the pharmaceutical, biotechnology and other related markets that address rare genetic diseases.
Aeglea Biotherapeutics trades on the NASDAQ stock market under the symbol AGLE.
As of September 27, 2023, AGLE stock price climbed to $11.49 with 14,484 million shares trading.
AGLE has a beta of 1.37, meaning it tends to be more sensitive to market movements. AGLE has a correlation of 0.02 to the broad based SPY ETF.
AGLE has a market cap of $46.51 million. This is considered a Sub-Micro Cap stock.
Last quarter Aeglea Biotherapeutics reported $688,000 in Revenue and -$41.50 earnings per share. This beat revenue expectation by $488,000 and missed earnings estimates by -$37.75.
In the last 3 years, AGLE stock traded as high as $247.50 and as low as $2.66.
The top ETF exchange traded funds that AGLE belongs to (by Net Assets): VXF, DFAC.
AGLE has underperformed the market in the last year with a price return of +1.1% while the SPY ETF gained +18.7%. However, in the short term, AGLE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +21.3% vs -0.9% return in SPY. But in the last 2 weeks, AGLE shares have been beat by the market, returning -17.0% compared to an SPY return of -4.1%.
AGLE support price is $10.15 and resistance is $12.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGLE stock will trade within this expected range on the day.